Back to results
US 6,323,211 B1Granted
Compositions and methods for treating sexual dysfunctions
AssigneeNitroMed, Inc.
InventorsDavid S. Garvey, Joseph D. Schroeder, Inigo Saenz de Tejada
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeNitroMed, Inc.
InventorsDavid S. Garvey, Joseph D. Schroeder, Inigo Saenz de Tejada
Estimating the term…
The present invention describes methods for preventing and treating sexual dysfunctions in patients by orally administering at least one α-adrenergic receptor antagonist and at least one compound that elevates endogenous nitric oxide or endothelium-derived relaxing factor in vivo. The present invention also describes orally administrable compositions comprising at least one α-adrenergic receptor antagonist and at least one compound that elevates endogenous nitric oxide or endothelium-derived relaxing factor in vivo. In the present invention, the α-adrenergic receptor antagonist is preferably yohimbine or phentolamine, and the compound that elevates endogenous nitric oxide or endothelium-derived relaxing factor in vivo is preferably L-arginine.
A method for treating a sexual dysfunction in a patient in need thereof comprising orally administering L-arginine in an amount of about 0.25 grams to about 10 grams or a pharmaceutically acceptable salt thereof and yohimbine in an amount of about 1.0 mg to about 18.0 mg or a pharmaceutically acceptable salt thereof to the patient about 15 minutes to about 125 minutes prior to sexual activity or sexual intercourse to treat the sexual dysfunction.
An orally administrable effervescent composition comprising L-arginine in an amount of about 0.25 grams to about 10 grams or a pharmaceutically acceptable salt thereof and yohimbine in an amount of about 1.0 milligrams to about 18.0 milligrams or a pharmaceutically acceptable salt thereof.
A sachet comprising L-arginine in an amount of about 0.25 grams to about 10.0 grams or a pharmaceutically acceptable salt thereof and yohimbine in an amount of about 1.0 milligrams to about 18.0 milligrams or a pharmaceutically acceptable salt thereof, wherein the L-arginine or the pharmaceutically acceptable salt thereof and the yohimbine or the pharmaceutically acceptable salt thereof are in an orally administrable form.
Dependencies are inferred from the claim text.